Skylands Capital’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Skylands Capital’s Portfolio ARIA Stock Details ARIA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-132,600	Closed	-$829K	–	212
2015 Q4	$829K	Hold	132,600	–	–	0.12%	128
2015 Q3	$774K	Hold	132,600	–	–	0.1%	135
2015 Q2	$1.1M	Sell	132,600 -7,000	-5%	-$61.9K	0.12%	144
2015 Q1	$1.15M	Sell	139,600 -4,500	-3%	-$33.3K	0.12%	139
2014 Q4	$990K	Hold	144,100	–	–	0.1%	150
2014 Q3	$778K	Sell	144,100 -25,400	-15%	-$148K	0.08%	161
2014 Q2	$1.08M	Buy	169,500 +17,250	+11%	+$119K	0.11%	156
2014 Q1	$1.23M	Buy	152,250 +2,250	+2%	+$17.5K	0.13%	130
2013 Q4	$1.02M	Buy	+150,000	New	+$810K	0.11%	143

Other funds holding ARIA

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Skylands Capital's ARIA Position: Q1 2016 in Review

Skylands Capital sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2016, closing a stake of 132,600 shares — an estimated $829K sold.

Skylands Capital first reported a position in ARIA in Q4 2013 and held it in 9 quarters. The position peaked at $1.23M in Q1 2014. 162 funds tracked by Wall St. Rank hold ARIA as of Q1 2016.

Skylands Capital reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
Skylands Capital sold 132,600 Ariad Pharmaceuticals Inc shares in Q1 2016, an estimated $829K.
Skylands Capital first reported a position in Ariad Pharmaceuticals Inc in Q4 2013 and held it in 9 quarters.
Skylands Capital's Ariad Pharmaceuticals Inc position peaked at $1.23M in Q1 2014.
162 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2016.

Based on Skylands Capital's 13F filing for Q1 2016, filed 14 Apr 2016.